Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Glasgow, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC

2863

Studies in scope

industry-sponsored, all four open statuses

1385

Recruiting now

open to new participants

542

Lead sponsors

across recruiting studies

Top sites

London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425

Trials with a site in Glasgow

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Birmingham, London, Glasgow, Cardiff, Manchester

2027-11-23

Recruiting

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases

DrugZenpep

Aimmune Nestlé Health Science US R&D, LLC

Phase 2

Liverpool, Belfast, Glasgow, Newcastle upon Tyne

2026-10

Not yet open

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer

DrugsPorustobart·Keytruda·Pembrolizumab

Solstice Oncology, Inc.

Phase 2

100

Aberdeen, Cardiff, Glasgow, Leeds, London

2026-09-30

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham

2026-09-29

Not yet open

The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis

NCT07746843Mild Knee Osteoarthritis, Moderate Knee Osteoarthritis

BioRegen Biomedical (Changzhou) Co., Ltd

Not applicable

286

Glasgow

2026-09-01

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugsBalcinrenone/dapagliflozin·Dapagliflozin

AstraZeneca

Phase 3

2,800

Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea

2026-09-01

Recruiting

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Epitopea Ltd

Phase 1

Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton

2026-09

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

1,560

Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington

2026-08-28

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

Bristol, Glasgow, Leicester, London, Oxford

2026-08-26

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Aberdeen, Cardiff, Corby, Coventry, Dundee, Glasgow, Leicester, Liverpool

2026-08-21

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Bodmin, Edinburgh, Exeter, Glasgow, Liverpool, Motherwell, Oxford, Penzance

2026-08-14

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford

2026-08-05

Recruiting

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

NCT06593392Pruritus, Chronic Kidney Diseases

Vifor Fresenius Medical Care Renal Pharma

Phase 2

Glasgow, Liverpool

2026-08-04

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Blackpool, Glasgow, Hull, Penzance, Sandbach, Thetford, Whitney

2026-07-06

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Ashton-under-Lyne, Blackpool, Chesterfield, Corby, Ely, Glasgow, Hounslow, Leicester

2026-06-29

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol

2026-06-01

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield

2026-05-20

Recruiting

A Study of TAK-755 in Adults With Acute Ischemic Stroke

NCT07392450Acute Ischemic Stroke

DrugTAK-755

Takeda

Phase 2

222

Cornhill, Luton, Glasgow, London

2026-05-17

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow

2026-05-14

Recruiting

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395Rhinovirus Infection

Altesa Biosciences, Inc.

Phase 2

180

Bromborough, Glasgow, London, Milton Keynes, Wolverhampton

2026-05-01

By invitation

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

NCT07393373Hypochondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

135

Manchester, Sheffield, Glasgow

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Cambridge, Glasgow, London

2026-04-23

Recruiting

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

NCT07441876Achondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 2/3

160

Bristol, Glasgow, Liverpool, London, Manchester

2026-04-20

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton

2026-04-09

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford

2026-03-24

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Glasgow, London, Manchester

2026-03-23

Active, closed

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

NCT07496450Influenza

ModernaTX, Inc.

Phase 3

4,050

Bristol, High Wycombe, Peterborough, Stockton-on-Tees, Bournemouth, Weymouth, Glasgow, Enfield

2026-03-23

Recruiting

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603Lichen Planopilaris

DrugBrepocitinib

Priovant Therapeutics, Inc.

Phase 2/3

342

Salford, Glasgow, Brighton, London, Wrexham

2026-03-19

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

London, Glasgow, Metropolitan Borough of Wirral

2026-03-16

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne

2026-03-16

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

London, Oxford, Sutton, Glasgow, Manchester

2026-03-13

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

360

Truro, London, Glasgow, Cardiff, Salford, Swansea

2026-03-10

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Cambridge, Glasgow, London, Sheffield, Swindon

2026-03-03

Active, closed

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2

DrugBerobenatide

Pfizer

Phase 3

1,078

Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston, Enfield

2026-02-24

Recruiting

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283Opioid Use Disorder

DrugsBuprenorphine·Brenipatide

Eli Lilly and Company

Phase 2

465

Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton

2026-02-13

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Bristol, Glasgow, Leicester, London, Oxford

2026-02-13

Recruiting

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham

2026-02-09

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York

2026-02-09

Active, closed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

NCT07234942Alzheimer's Disease

Hoffmann-La Roche

Phase 1

London, Southampton, Glasgow

2026-01-27

Recruiting

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

CSL Behring

Phase 2

Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford

2026-01-22

Recruiting

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT07053800Lupus Nephritis

DrugObecabtagene autoleucel

Autolus Limited

Phase 2

Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester

2026-01-16

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Cambridge, Glasgow, Manchester

2026-01-15

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901Obesity With Diabetes, Overweight With Diabetes

DrugRibupatide

Kailera

Phase 3

1,270

Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester

2026-01-12

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton

2026-01-12

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton

2026-01-07

Recruiting

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

NCT07224581GRIN-related Neurodevelopmental Disorder

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 3

100

Sheffield, Glasgow, London

2026-01-05

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

NCT07284979Obesity

DrugsRibupatide·Wegovy·Semaglutide

Kailera

Phase 3

1,270

Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham

2025-12-30

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton

2025-12-19

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982Spinal Muscular Atrophy (SMA)

DrugARGX-119

argenx

Phase 2

Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds

2025-12-19

Active, closed

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850Obesity and Overweight

DrugBerobenatide

Pfizer

Phase 3

3,578

Sandbach, Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston

2025-12-19

Recruiting

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

NCT07300969Major Depressive Disorder (MDD)

DrugDT-101

Draig Therapeutics Ltd

Phase 2

300

Chester, Eastbourne, Glasgow, London, Nottingham, Oxford

2025-12-16

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Glasgow, Leeds, Luton, Staffordshire

2025-12-15

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Birmingham, Glasgow, Liverpool, London, Manchester

2025-12-15

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

DrugCYB003

Cybin IRL Limited

Phase 3

330

Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield

2025-12-10

Recruiting

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665Clostridoides Difficile Associated Disease

Pfizer

Phase 3

32,500

Newquay, Exeter, Plymouth, Torquay, Preston, Glasgow, Southampton, Blackpool

2025-12-10

Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

120

Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton

2025-12-09

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Birmingham, Glasgow, Greater London, Leeds, London, Manchester

2025-12-04

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Leeds, Bristol, Cambridge, Glasgow, North Finchley

2025-11-25

Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum

Crinetics Pharmaceuticals Inc.

Phase 3

141

London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton

2025-11-19

Recruiting

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279Achondroplasia

QED Therapeutics, a BridgeBio company

Phase 2

Glasgow, Manchester, Sheffield

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol

2025-11-19

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston

2025-11-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Brighton, Romford, Coventry, Glasgow, Leeds, London, Nottingham

2025-11-11

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Glasgow, London, Sulton, Surrey

2025-11-05

Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura

DrugEfgartigimod

argenx

Phase 2/3

Cardiff, Glasgow, Manchester

2025-10-20

Recruiting

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay

2025-10-16

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne

2025-10-15

Recruiting

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT07214727Alzheimer's Disease

Alnylam Pharmaceuticals

Phase 1

Glasgow, London, Sheffield, Southampton

2025-10-15

Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton

2025-10-15

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

London, Glasgow, Oxford

2025-10-06

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport

2025-10-03

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Glasgow, London, Sheffield

2025-09-30

Recruiting

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

NCT06865417Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield

2025-09-29

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne

2025-09-08

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London

2025-08-14

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232Advanced Solid Tumor

DrugsBNT326·Paroxetine·Itraconazole·Pumitamig

BioNTech SE

Phase 1/2

1,438

Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton

2025-08-12

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford

2025-08-06

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Cambridge, Bathgate, Rickmansworth, Maidstone, Taunton, Cottingham, Glasgow, Leeds

2025-07-24

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Edinburgh, Glasgow, London, Cardiff, Manchester

2025-07-20

Active, closed

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

NCT06963710Chronic Hepatitis B Infection

DrugALG-000184

Aligos Therapeutics

Phase 2

200

Glasgow, Leicester, London

2025-07-15

Active, closed

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078Chronic Obstructive Pulmonary Disease

DrugVerekitug

Upstream Bio Inc.

Phase 2

666

Milton Keynes, Edgbaston, High Wycombe, Chesterfield, Newton Abbot, Romford, Glasgow, Preston

2025-07-02

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe

2025-06-27

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Glasgow, Leicester, London, Manchester, Sheffield, Southampton

2025-06-24

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

961

Manchester, Portsmouth, Uxbridge, Bedford, Corby, Dagenham, Edinburgh, Glasgow

2025-06-23

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport

2025-06-17

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Glasgow, London, Sheffield

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Cardiff, Glasgow, Leeds, Leicester, London

2025-06-04

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

Glasgow, London

2025-05-30

Recruiting

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease

NCT06872905Aortoiliac Occlusive Disease

W.L.Gore & Associates

Observational

158

Glasgow

2025-05-30

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Birmingham, Glasgow, London

2025-05-27

Recruiting

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

NCT06978660Transthyretin Cardiac Amyloidosis

Idoven 1903 S.L.

Observational

2,200

Glasgow

2025-05-27

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester

2025-05-22

Active, closed

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479Severe Asthma

DrugVerekitug

Upstream Bio Inc.

Phase 2

396

Cottingham, Glasgow, Chertsey, Perth, Bradford, Oxford

2025-05-21

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford

2025-05-19

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Cambridge, London, Glasgow

2025-05-12

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD5492

AstraZeneca

Phase 1

Glasgow, London, Southampton

2025-05-01

Active, closed

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

AstraZeneca

Phase 1/2

Glasgow, London

2025-04-29

By invitation

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

NCT06926621Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 2

Glasgow, London, Sheffield

2025-04-28

By invitation

An Interventional Study of Infigratinib in Children With Hypochondroplasia

NCT06873035Hypochondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2/3

Manchester, Sheffield, Glasgow

2025-04-22

Recruiting

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248Multiple Sclerosis

DrugMRNA-1195

ModernaTX, Inc.

Phase 2

180

Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield

2025-04-16

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford

2025-04-10

Active, closed

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166COPD, Smoking, Tobacco Use

Philip Morris Products S.A.

Not applicable

290

Enfield, Glasgow, High Wycombe, London, Manchester, Metropolitan Borough of Wirral, Preston, Rochdale

2025-04-02

Recruiting

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

NCT06977737Solid Tumor, Adult

Accession Therapeutics Limited

Phase 1/2

Glasgow, Cardiff, Leeds, Oxford

2025-03-21

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Bradford, Brighton, Cottingham, Glasgow, Halifax, Leeds, Portsmouth, Tyne and Wear

2025-03-18

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Bristol, Glasgow, Salford, Southampton

2025-03-18

Active, closed

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

1,105

Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester

2025-03-17

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance

2025-03-14

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Cambridge, Glasgow, London, Manchester

2025-03-13

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Glasgow, Northwood, London, Manchester

2025-03-13

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield

2025-03-11

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

DrugIntismeran autogene

Merck Sharp & Dohme LLC

Phase 2

308

Glasgow, London, Torquay

2025-03-11

Recruiting

Inari VISION Registry

NCT06600542Pulmonary Embolism

Inari Medical

Observational

1,000

Bristol, Glasgow, London, Newcastle, Swindon

2025-03-07

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Birmingham, Bournemouth, Glasgow, Headington, London, Metropolitan Borough of Wirral, Plymouth

2025-03-05

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Glasgow, London

2025-03-04

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London

2025-03-03

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

London, Glasgow, Sutton

2025-02-28

Active, closed

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126Uveal Melanoma, Ocular Melanoma

DrugRoginolisib

iOnctura

Phase 2

Northwood, Bebington, Glasgow, London, Southampton

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London

2025-02-27

Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394Breast Neoplasms, Breast Cancer

DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib

Merck Sharp & Dohme LLC

Phase 1/2

181

London, Glasgow

2025-02-26

Recruiting

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

NCT06567782Neoplasms, Colon

DrugsCapeox·Dostarlimab

GlaxoSmithKline

Phase 2

120

Glasgow, Leeds West Yorkshire, London, Sutton

2025-02-18

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Cardiff, Newcastle upon Tyne, Glasgow, London

2025-02-12

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

London, Glasgow, Birmingham, Newcastle upon Tyne

2025-02-04

Active, closed

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

NCT06809595Generalized Anxiety Disorder

DrugDT120

Definium Therapeutics US, Inc.

Phase 3

245

Glasgow, Gosforth, London, Manchester, Sheffield

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester

2025-01-28

Recruiting

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer

DrugFamotidine

Epkin

Phase 1

146

Glasgow, Leicester, London, Manchester, Oxford

2025-01-23

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth

2025-01-21

Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant

DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine

Immatics US, Inc.

Phase 3

360

Cambridge, Glasgow, London, Manchester, Oxford, Southampton

2025-01-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Barnet, Basingstoke, Christchurch, Edinburgh, Glasgow, Hereford, Larbert, Staffordshire

2025-01-09

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Basildon, Bath, Brighton, Cardiff, Chelsea, Cottingham, Glasgow, Liverpool

2025-01-07

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Maidstone

2025-01-03

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

London, Edinburgh, Glasgow

2025-01-02

Recruiting

REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

NCT06922175Epilepsy With Uncontrolled Focal-onset Seizures

Aziende Chimiche Riunite Angelini Francesco S.p.A

Observational

200

Glasgow, Wolverhampton

2024-12-19

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Harefield, Southampton, Glasgow, Basingstoke, Cottingham, Dudley, Dundonald, Swindon

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Glasgow, Oxford, Salford, Sheffield, Taunton

2024-12-18

By invitation

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

NCT06709040Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2

DrugSomapacitan

Novo Nordisk A/S

Observational

500

Glasgow

2024-12-13

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Glasgow, London, Sutton

2024-12-09

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Glasgow, Manchester, Plymouth, Sutton, Tooting

2024-12-05

Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844Solid Tumor

Corbus Pharmaceuticals Inc.

Phase 1/2

156

Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London

2024-12-04

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Salford, Oxford, Glasgow, Newcastle upon Tyne, Exeter, London

2024-12-03

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Glasgow, London, Manchester, Nottingham, Plymouth

2024-11-25

By invitation

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06435312Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 3

Glasgow, London

2024-11-19

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

Aberdeen, Bristol, Camberley, Derby, Edgbaston, Birmingham, Exeter, Glasgow, Hull

2024-11-12

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London

2024-11-11

Recruiting

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499Metastatic Castration-Resistant Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 1

106

Sutton, Birmingham, Glasgow

2024-11-11

Active, closed

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

NCT06713135Duchenne Muscular Dystrophy

DrugVamorolone

Santhera Pharmaceuticals

Phase 4

Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle

2024-11-10

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Blackburn, Chelmsford, Derby, Glasgow, Metropolitan Borough of Wirral

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea

2024-10-21

Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860Diabetic Peripheral Neuropathic Pain

DrugPregabalin

Vertex Pharmaceuticals Incorporated

Phase 2

300

Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield

2024-10-18

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro

2024-10-18

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 2/3

Glasgow, London

2024-10-16

Recruiting

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT06585449Huntington's Disease

Alnylam Pharmaceuticals

Phase 1

Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2024-10-11

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough

2024-10-04

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Cambridge, Glasgow, Bradford, Chertsey, London

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne

2024-09-30

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Newcastle upon Tyne, Glasgow, London

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Glasgow, Leicester, Liverpool, London

2024-09-24

Recruiting

Trial of THEO-260 in Ovarian Cancer Patients

NCT06618235Ovarian Cancer

DrugTHEO-260

Theolytics Limited

Phase 1/2

Glasgow, London, Oxford

2024-09-24

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay

2024-09-23

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Brighton, Glasgow, Leeds, London, Southampton

2024-09-18

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Glasgow, Birmingham, Cambridge, London

2024-09-11

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff

2024-09-04

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London

2024-08-30

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton

2024-08-28

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Cambridge, Glasgow, Manchester

2024-08-22

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

675

Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne

2024-08-19

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton

2024-08-13

Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies

DrugPelabresib

Novartis Pharmaceuticals

Phase 3

Cardiff, Glasgow, London

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Birmingham, Dundee, Glasgow, Greater London, Leeds, London

2024-08-12

Active, closed

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109Alopecia Areata

DrugRitlecitinib

Pfizer

Observational

450

Brighton, Dunfermline, Gloucester, Bath, Glasgow, London

2024-08-07

Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

NCT06297525Solid Tumor

DrugSTP938

Step Pharma, SAS

Phase 1

Glasgow, London, Manchester

2024-08-02

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne

2024-07-30

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

London, Sutton, Glasgow, Leeds, Manchester

2024-07-24

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley

2024-07-19

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton

2024-07-17

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Birmingham, Glasgow, London

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Truro, Torquay, Bournemouth, Ashford, Blackpool, Harefield, Edinburgh, Glasgow

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne

2024-06-25

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays

2024-06-05

Recruiting

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976Hypochondroplasia

QED Therapeutics, a BridgeBio company

Observational

150

London, Manchester, Sheffield, Glasgow

2024-06-05

Recruiting

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

NCT06372717Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse

Apollo Therapeutics Ltd

Phase 1

100

Cardiff, Glasgow, London

2024-06-04

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201Select Advanced Solid Tumors

CDR-Life AG

Phase 1

Sutton, Glasgow, London

2024-05-24

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Cambridge, Glasgow, Preston, London, Birmingham

2024-05-20

Active, closed

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

NCT06393712Cerebral Amyloid Angiopathy

DrugsAln-App·Mivelsiran

Alnylam Pharmaceuticals

Phase 2

210

Glasgow, London

2024-05-17

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492Dravet Syndrome

DrugETX101

Encoded Therapeutics

Phase 1/2

Glasgow, London

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne

2024-05-13

Active, closed

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

NCT06283212Dravet Syndrome

DrugETX101

Encoded Therapeutics

Phase 1/2

Glasgow, London, Sheffield

2024-05-09

Active, closed

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

NCT06294925Colitis, Ulcerative

DrugEtrasimod

Pfizer

Observational

360

Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport

2024-05-08

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Portsmouth, Leicester, London, Glasgow

2024-05-08

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Aberdeen, Birmingham, Bromborough, Coventry, Glasgow, Hull, Ipswich, Lancashire

2024-04-30

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Glasgow, Manchester, Sheffield

2024-04-22

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Glasgow, Leeds

2024-04-16

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Cambridge, Glasgow, London, Edinburgh, Manchester

2024-04-10

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Bristol, Cambridge, Dundee, Glasgow, Harrow, Hounslow, Leicester, Liverpool

2024-03-29

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Torquay, London, Glasgow, Manchester

2024-03-28

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Cambridge, Glasgow, London, Oxford

2024-03-23

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton

2024-03-18

Active, closed

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603Type 2 Diabetes

DrugRetatrutide

Eli Lilly and Company

Phase 3

320

Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage

2024-03-15

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Glasgow, London, Manchester, Oxford, Sheffield

2024-03-13

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston

2024-03-13

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne

2024-03-05

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT05935215Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Glasgow, Newcastle upon Tyne, London

2024-02-28

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Bath, Glasgow, Headington, London, Northampton

2024-02-27

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

307

Glasgow, London

2024-02-21

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

London, Glasgow, Manchester, Sutton

2024-02-21

Active, closed

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 1/2

Glasgow, London, Salford, Sheffield

2024-02-20

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT05933057Duchenne Muscular Dystrophy

DrugHydroxyurea

Italfarmaco

Phase 3

138

Newcastle upon Tyne, Oxford, Glasgow

2024-02-19

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

NCT05970172Chronic Kidney Disease, Renal Anemia

DrugRoxadustat

Astellas Pharma Global Development, Inc.

Phase 3

100

Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton

2024-01-16

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

Birmingham, Cardiff, Glasgow, Hexham, London, Manchester

2024-01-11

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Cambridge, Truro, Glasgow, London, Manchester

2023-12-31

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford

2023-12-18

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Glasgow, Leeds, London, Oxford

2023-12-13

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Truro, Plymouth, Bournemouth, Glasgow, Norwich, Romford

2023-12-12

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow

2023-12-11

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

East Sussex, Derby, London, Truro, Glasgow, Manchester

2023-12-06

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton

2023-11-29

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056Bronchiectasis

Chiesi Farmaceutici S.p.A.

Phase 1/2

Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton

2023-11-29

Recruiting

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

NCT06212947Hypochondroplasia

BioMarin Pharmaceutical

Observational

400

London, Glasgow

2023-11-27

Active, closed

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06173531Hyperphagia in Prader-Willi Syndrome

DrugCarbetocin

ACADIA Pharmaceuticals Inc.

Phase 3

170

Birmingham, Glasgow, London

2023-11-27

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne

2023-11-21

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Cardiff, Dundee, Glasgow, London, York

2023-11-07

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

Glasgow, Metropolitan Borough of Wirral, Northwood

2023-10-31

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth

2023-10-23

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Glasgow, Lincoln, London, Manchester, Oxford, Plymouth

2023-10-22

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Manchester, Leeds, Cardiff, Glasgow, London

2023-10-20

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle

2023-09-18

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Plymouth, London, Glasgow, Guildford, Cardiff

2023-09-09

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Birmingham, Glasgow, London

2023-08-31

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Dundee, Glasgow, Liverpool, London, Oxford

2023-08-31

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent

2023-08-24

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

NCT05907304Advanced or Metastatic Solid Tumors

DrugsNaporafenib·Trametinib

Erasca, Inc.

Phase 1

City of London, Glasgow

2023-08-17

Active, closed

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Glasgow, London

2023-08-16

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

Sutton, Barnet, Cambridge, Glasgow, Middlesbrough

2023-08-14

Active, closed

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553SCN2A Encephalopathy, SCN8A Encephalopathy

DrugRelutrigine

Praxis Precision Medicines

Phase 2/3

Glasgow, London

2023-08-02

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Newquay, Fowey, Glasgow, Chippenham, Cambridge, Carshalton, London, Plymouth

2023-07-14

Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1/2

230

Glasgow, London, Manchester, Newcastle upon Tyne, Oxford

2023-07-06

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Glasgow, London

2023-06-20

Recruiting

eUltra 10k - Biofreedom Ultra

NCT05505929Post Market Clinical Follow up (PMCF)

Biosensors Europe SA

Observational

10,000

Bournemouth, Glasgow

2023-06-15

Active, closed

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

MeiraGTx, LLC

Phase 2

290

Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York

2023-06-13

Active, closed

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Observational

509

Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton

2023-06-12

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Edinburgh, Great Yarmouth, Glasgow, London

2023-06-08

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Glasgow, Salford, Doncaster

2023-05-20

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne

2023-05-03

Active, closed

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

NCT07304843Primary Biliary Cholangitis (PBC)

Umecrine Cognition AB

Phase 1/2

202

Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton

2023-04-14

Active, closed

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359Parkinson's Disease

Bial R&D Investments, S.A.

Phase 2

237

Dundee, Glasgow, London, Newcastle upon Tyne, Plymouth

2023-03-31

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Birmingham, Newcastle upon Tyne, Chelsea, Glasgow, London

2023-03-30

Active, closed

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

NCT05818943GRIN-related Disorders

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1

Glasgow, London

2023-03-07

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

London, Blackburn, Glasgow, Manchester

2023-03-03

Active, closed

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774Prader-Willi Syndrome

Soleno Therapeutics, Inc.

Phase 3

Cambridge, Glasgow, Hull, London

2023-01-31

Recruiting

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06311708Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics

Observational

200

Glasgow, London

2023-01-31

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London

2023-01-23

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Glasgow, Oxford

2023-01-18

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Plymouth, Cringleford, Glasgow, Birmingham, Leeds, Taunton

2023-01-10

By invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386Hemophilia A

BioMarin Pharmaceutical

Observational

172

Cambridge, Glasgow, London, Oxford, Southampton

2023-01-01

Recruiting

Clinical Feasibility of the IMES Transradial Prosthesis

NCT04936789Amputation

Össur Iceland ehf

Not applicable

Glasgow

2023-01-01

Active, closed

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 2

Aberdeen, Birmingham, Frimley, Glasgow, Hull, London

2022-12-29

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Bollington, Blackpool, Brierley Hill, Corby, Glasgow, Hayle, High Wycombe, Isleworth

2022-12-27

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London

2022-12-13

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Glasgow, Gloucester, London, Newport

2022-11-21

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow

2022-11-10

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool

2022-11-08

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

London, Manchester, Nottingham, Glasgow

2022-11-08

Active, closed

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299End-stage Renal Disease

Xeltis

Not applicable

120

Birmingham, Glasgow

2022-11-04

Active, closed

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

NCT05120271Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma

Sotio Biotech Inc.

Phase 1/2

Glasgow, London

2022-10-26

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

Glasgow, London, Nottingham, Oxford

2022-10-26

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester

2022-10-24

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

London, Liverpool, Glasgow, Redhill, Aberdeen

2022-10-14

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Birmingham, Devon, Glasgow, London, Sheffield

2022-09-23

Active, closed

The Euro-CRAFT Registry

NCT05805462Coronary Microvascular Disease

CoreAalst BV

Observational

671

Bath, Bristol, Essex, Glasgow, London, Oxford

2022-09-22

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford

2022-09-19

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697Advanced Solid Tumors

DrugsIpilimumab·Nivolumab·Pembrolizumab

ModernaTX, Inc.

Phase 1/2

361

Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton

2022-09-01

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool

2022-08-22

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Edinburgh, Glasgow, Leeds, London, Nottingham

2022-07-25

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton

2022-07-22

Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms

Blue Earth Therapeutics Ltd

Phase 1/2

Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton

2022-07-20

Recruiting

Collection of Blood Samples for New Diagnostic Devices 2

NCT05568966Embolism and Thrombosis, Cardiovascular, Renal, Inflammation

LumiraDx UK Limited

Observational

20,000

Airdrie, Edinburgh, Glasgow, Paisley

2022-07-11

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton

2022-07-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

DrugTaldefgrobep alfa

Biohaven Pharmaceuticals, Inc.

Phase 3

269

Glasgow, Oxford

2022-07-06

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford

2022-06-16

Active, closed

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440Metastatic Prostate Cancer

DrugsSaruparib·Zytiga·Apalutamide·Xtandi

AstraZeneca

Phase 1/2

174

Cambridge, Glasgow, Manchester, Plymouth

2022-06-02

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London

2022-05-30

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Glasgow, London, Manchester

2022-05-22

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619Lupus Nephritis

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Mycophenolate Mofetil·Methylprednisolone

Hoffmann-La Roche

Phase 2

Glasgow, Liverpool, London

2022-05-12

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Glasgow, Cambridge, London, Manchester, Merseyside

2022-05-03

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Glasgow, Leeds, London, Southampton

2022-04-26

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Cambridge, Glasgow, London, Manchester, Sheffield

2022-04-14

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton

2022-04-13

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

London, Manchester, Nottingham, Glasgow

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton

2022-03-25

Active, closed

Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

NCT05269862Parkinson Disease

Abbott Medical Devices

Not applicable

100

Glasgow

2022-03-24

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

London, Nottingham, Glasgow, Manchester, Swansea

2022-03-15

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton

2022-03-10

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Manchester, Glasgow, London

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Birmingham, Glasgow, London, Oxford, Salford

2022-02-03

Recruiting

The "Global Paradise System" Registry

NCT05027685Hypertension

ReCor Medical, Inc.

Observational

3,000

Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle

2022-01-13

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,000

Westbruy on Trym, Winchester, Glasgow

2021-12-16

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham

2021-12-10

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Birmingham, Cardiff, Glasgow, London, Oxford, Salford

2021-12-07

By invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

NCT05145010Achondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

300

Birmingham, Bristol, Glasgow, London, Manchester, Sheffield

2021-12-06

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

London, Edinburgh, Great Yarmouth, Glasgow

2021-12-01

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2021-11-17

Active, closed

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

NCT05163041Advanced Solid Tumor

DrugNivolumab

BicycleTx Limited

Phase 1/2

200

Sutton, Glasgow

2021-11-02

Active, closed

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

NCT05112237Cardiomyopathy

Tenaya Therapeutics

Observational

200

Glasgow, London

2021-11-01

Recruiting

Safety of Splenic Stimulation for RA

NCT04955899Rheumatoid Arthritis

Galvani Bioelectronics

Not applicable

Glasgow

2021-10-20

Active, closed

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms

W.L.Gore & Associates

Observational

614

Bristol, Glasgow, London

2021-10-09

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma

DrugPaclitaxel

Nurix Therapeutics, Inc.

Phase 1

345

Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford

2021-09-29

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

Aberdeen, Abergavenny, Airdrie, Barnet, Bath, Glasgow, Hull, Leeds

2021-08-25

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow

2021-08-19

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Cambridge, London, Glasgow

2021-08-12

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

Bristol, Glasgow, Liverpool, London, Manchester

2021-08-12

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Glasgow, Newcastle upon Tyne, London

2021-07-28

Active, closed

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer

Avacta Life Sciences Ltd

Phase 1

158

Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield

2021-07-16

Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675Chronic Migraine in Children

DrugEptinezumab

H. Lundbeck A/S

Phase 3

285

Exeter, Edinburgh, Great Yarmouth, Glasgow, London

2021-06-30

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Glasgow, London-Camden, Cardiff, Coventry

2021-06-25

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London

2021-06-24

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Sutton, Belfast, Cambridge, Glasgow, London, Middlesbrough

2021-06-09

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester

2021-05-21

Active, closed

The SELUTION DeNovo Study

NCT04859985Coronary Artery Disease

M.A. Med Alliance S.A.

Not applicable

3,326

Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester

2021-05-15

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London

2021-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield

2021-05-12

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

Birmingham, Dundee, Glasgow, Liverpool, London, Oxford

2021-05-06

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham

2021-04-24

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor

2021-04-08

Active, closed

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III

DrugAutogene cevumeran

BioNTech SE

Phase 2

327

Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester

2021-03-08

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Bristol, Cardiff, Glasgow, London

2021-03-04

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Birmingham, Edinburgh, Glasgow, Leicester, Manchester

2021-02-23

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Glasgow, Leeds, London, Manchester, Nottingham

2021-02-23

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726Severe Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Glasgow

2021-02-04

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer

DrugsIrinotecan·Gemcitabine

Artios Pharma Ltd

Phase 1/2

542

Glasgow, London, Manchester

2021-01-27

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Glasgow, London, Manchester

2021-01-18

Active, closed

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04204616Prurigo Nodularis

DrugNemolizumab

Galderma R&D

Phase 3

500

Dudley, Glasgow, London, Newcastle upon Tyne

2021-01-11

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester

2021-01-10

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2021-01-07

Active, closed

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer

DrugsAvutometinib (VS-6766) and defactinib·Avutometinib·Lumakras

Verastem, Inc.

Phase 2

225

Edinburgh, Glasgow, London, Manchester, Sutton

2020-12-21

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

Glasgow, Leeds

2020-12-18

Active, closed

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04794101X-Linked Retinitis Pigmentosa

MeiraGTx Ocular UK Ltd

Phase 3

Edinburgh, Glasgow, Leeds, London

2020-12-04

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey

2020-11-17

Active, closed

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Bayer

Phase 4

654

Reading, Glasgow

2020-11-09

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Glasgow, London

2020-11-03

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Glasgow, London, Nottingham, Swansea

2020-10-26

Active, closed

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226Cancer

DrugDarolutamide

Bayer

Phase 3

402

Reading, Colchester, London, Bebington, Scunthorpe, Glasgow, Cardiff, Llanelli

2020-10-20

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham

2020-09-30

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Sutton, Glasgow, Manchester

2020-09-16

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556Solid Tumor

DrugsPrednisolone·Lenvatinib·Prednisone·Dexamethasone

Eisai Inc.

Phase 1/2

182

Belfast, Glasgow, Manchester, Preston, London, Northwood, Cardiff, Sutton

2020-08-06

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton

2020-08-04

Active, closed

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease

DrugLecanemab

Eisai Inc.

Phase 3

1,400

Bristol, Glasgow, London

2020-07-14

Active, closed

Linerixibat Long-term Safety, and Tolerability Study

NCT04167358Cholestasis

GlaxoSmithKline

Phase 3

242

Basingstoke, Glasgow, London, Newcastle upon Tyne, Nottingham, Plymouth, Reading Berkshire, Southampton

2020-07-14

Active, closed

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer

DrugTemozolomide

Sapience Therapeutics

Phase 1/2

125

Edinburgh, Glasgow, Leeds, London

2020-07-01

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Edinburgh, London, Bebington, Cornwell, Glasgow, Middlesex

2020-06-11

Active, closed

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

DrugAUTO1

Autolus Limited

Phase 1/2

153

Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol

2020-06-03

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton

2020-03-30

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors

DrugRepotrectinib

Turning Point Therapeutics, Inc.

Phase 1/2

Liverpool, Birmingham, Cardiff, Glasgow, London

2020-03-12

Active, closed

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer

ImCheck Therapeutics, an Ipsen company

Phase 1/2

293

Glasgow, London

2020-03-05

Active, closed

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750Carcinoma, Renal Cell

DrugsBelzutifan·Everolimus

Merck Sharp & Dohme LLC

Phase 3

755

Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester

2020-02-27

Active, closed

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

NCT04328844Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis

DrugsRoginolisib·Avelumab·Ruxolitinib·Pemetrexed

iOnctura

Phase 1

210

Glasgow

2020-02-25

Active, closed

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466Select Advanced Solid Tumors

DrugBrenetafusp

Immunocore Ltd

Phase 1/2

410

London, Oxford, Glasgow, Liverpool, Manchester, Surrey Quays

2020-02-25

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Cardiff, Sheffield, Glasgow, London

2020-02-11

Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT03934372Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia

DrugPonatinib

Incyte Biosciences International Sàrl

Phase 1/2

Glasgow, Liverpool, Sutton

2020-01-29

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds

2020-01-16

Active, closed

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206Moderate-to-Severe Atopic Dermatitis

DrugNemolizumab

Galderma R&D

Phase 3

1,700

Barnsley, Blackpool, Cannock, Dudley, Glasgow, Liverpool, London, Manchester

2019-12-30

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03969329Secondary Hyperparathyroidism

DrugEtelcalcetide

Amgen

Phase 3

Glasgow, Leeds, London, Southampton

2019-12-20

Recruiting

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor

Abbott Medical Devices

Observational

1,000

Liverpool, Bristol, Glasgow, London

2019-11-26

Active, closed

First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)

NCT04203576Heart Failure

Foundry Innovation & Research 1, Limited (FIRE1)

Not applicable

Bournemouth, Glasgow, Leicester, London, Portsmouth, Southampton

2019-11-22

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Glasgow, London

2019-09-26

By invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension

United Therapeutics

Phase 3

1,000

London, Newcastle upon Tyne, Glasgow

2019-09-23

Active, closed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339Diabetic Cardiomyopathies

Applied Therapeutics, Inc.

Phase 3

675

Dundee, Glasgow, Leicester, London, Manchester

2019-09-20

Active, closed

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005Multiple Sclerosis, Primary Progressive

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,013

Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford

2019-08-12

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

London, Manchester, Southampton, Maidstone, Northwood, Edinburgh, Glasgow

2019-08-09

Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma

DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide

CellCentric Ltd.

Phase 1/2

250

Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester

2019-08-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

NCT03861273Hemophilia B

Pfizer

Phase 3

Newcastle upon Tyne, Glasgow, London

2019-07-29

Active, closed

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

NCT03836040Migraine

Amgen

Phase 3

457

Cardiff, Glasgow, Liverpool, London, Manchester, Oxford

2019-07-19

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsCabozantinib·Yervoy·Ipilimumab·Opdivo

Exelixis

Phase 3

855

Cambridge, Glasgow, London, Manchester

2019-06-25

Active, closed

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

415

Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester

2019-06-04

Active, closed

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260Indolent Systemic Mastocytosis

DrugAvapritinib

Blueprint Medicines Corporation

Phase 2

251

Glasgow, London, Metropolitan Borough of Wirral

2019-04-16

Recruiting

Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796Ovarian Cancer

Allarity Therapeutics

Observational

Glasgow, London

2019-04-11

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

NCT03813407Hyperkalaemia

DrugPumitamig

AstraZeneca

Phase 3

140

Glasgow, Hampshire, Manchester, Nottingham

2019-04-02

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

London, Glasgow, Stafford, Manchester, Metropolitan Borough of Wirral, Portsmouth, Torquay

2019-03-25

Active, closed

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501Gastrointestinal Stromal Tumors

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

453

Glasgow, Leeds, London, Sheffield

2019-02-08

Active, closed

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962Focal Epilepsy

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 2

325

Glasgow, Cardiff, London

2019-01-30

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Luton, Glasgow, Sheffield, London, Oxford

2018-12-28

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield

2018-11-28

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth

2018-10-22

Active, closed

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT03602859Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

DrugsNiraparib·Dostarlimab

Tesaro, Inc.

Phase 3

1,400

Glasgow, Metropolitan Borough of Wirral, Portsmouth, Sutton, Truro

2018-10-11

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

DrugCabozantinib

Exelixis

Phase 3

187

Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester

2018-10-05

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston

2018-08-21

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

London, Oxford, Dundee, Glasgow, Leeds

2018-08-09

By invitation

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric

Autolus Limited

Phase 2

500

Glasgow, London, Manchester, Newcastle upon Tyne

2018-08-02

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton

2018-05-14

Active, closed

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell

DrugsChlorambucil·Ibrutinib·Obinutuzumab·Venetoclax

Janssen Research & Development, LLC

Phase 3

211

Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield

2018-04-17

Active, closed

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922Melanoma

DrugsRelatlimab·Nivolumab

Bristol-Myers Squibb

Phase 2/3

714

Bristol, Glasgow, Swansea, London, Inverness

2018-04-11

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford

2018-04-09

Active, closed

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373Neuroblastoma

DrugsNaxitamab·Gm-Csf

Y-mAbs Therapeutics

Phase 2

122

Glasgow, Leeds, Southampton

2018-04-03

Active, closed

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)

DrugAZD1390

AstraZeneca

Phase 1

159

Cambridge, Glasgow, Leeds

2018-04-02

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005Metastatic Breast Cancer

DrugsAtirmociclib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 1/2

1,132

Glasgow, London

2018-03-30

Active, closed

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03436485Prostate Cancer Metastatic

DrugsOpevesostat·Midazolam

Orion Corporation, Orion Pharma

Phase 1/2

204

Bedlington, Cardiff, Glasgow, Liverpool, London, Manchester, Preston

2018-03-19

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London

2017-12-18

Active, closed

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma

DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab

Replimune, Inc.

Phase 2

340

Leeds, Oxford, Glasgow, Bebington, London, Southampton

2017-09-20

Recruiting

Registry for Patients With X-Linked Hypophosphatemia

NCT03193476X-Linked Hypophosphatemia

Kyowa Kirin Pharmaceutical Development Ltd

Observational

1,489

Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness

2017-09-12

Active, closed

Study of E7386 in Participants With Selected Advanced Neoplasms

NCT03264664Advanced Neoplasms

DrugE7386

Eisai Inc.

Phase 1

Glasgow, Manchester, Sutton, London

2017-07-27

Active, closed

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugPacritinib

Swedish Orphan Biovitrum

Phase 3

407

Sheffield, Glasgow, London, Gloucester, Oxford

2017-06-26

Active, closed

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633Acute Coronary Syndrome, High Bleeding Risk

Biosensors Europe SA

Not applicable

1,203

Bournemouth, Craigavon, Glasgow

2017-02-14

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield

2017-01-31

Active, closed

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661Muscle Invasive Bladder Cancer

DrugsDanvatirsen·Fexagratinib·Vistusertib·Adavosertib

AstraZeneca

Phase 1

117

Glasgow, London, Manchester, Southampton

2016-12-28

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide

Astellas Pharma Global Development, Inc.

Phase 2

900

Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester

2016-12-22

Recruiting

Fosfomycin I.v. for Treatment of Severely Infected Patients

NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections

Infectopharm Arzneimittel GmbH

Observational

1,000

Bolton, Cottingham, Dundee, Glasgow, Kilmarnock, London

2016-12

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906Neoplasms

DrugCetrelimab

Janssen Research & Development, LLC

Phase 1/2

234

Glasgow, London, Manchester, Newcastle upon Tyne

2016-11-21

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester

2016-10-13

Active, closed

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT02655016Ovarian Neoplasms

DrugNiraparib

Tesaro, Inc.

Phase 3

733

Blackburn, Edinburgh, Exeter, Glasgow, London, Portsmouth, Sheffield, Truro

2016-07-11

Active, closed

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004Ovarian, Breast, SCLC, Gastric Cancers

DrugsAvastin·Olaparib·Durvalumab·Bevacizumab

AstraZeneca

Phase 1/2

264

Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton

2016-03-17

Recruiting

Vercise™ DBS Dystonia Prospective Study

NCT02686125Dystonia

Boston Scientific Corporation

Observational

300

Bristol, Glasgow, London, Newcastle upon Tyne

2016-03-07

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe

2015-11-27

Active, closed

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516Prostatic Neoplasms

DrugsGnRH·Bicalutamide·Apalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,503

Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston

2015-11-19

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield

2015-11-02

Active, closed

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423Solid Tumors, Lymphoma

DrugTolinapant

Taiho Oncology, Inc.

Phase 1/2

253

Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester

2015-07-14

Active, closed

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsLupron·Eligard·Leuprorelin·Xtandi

Pfizer

Phase 3

1,068

Glasgow, Wonford, London, Sutton, Birmingham, Bristol

2014-12-17

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone

Aragon Pharmaceuticals, Inc.

Phase 3

982

Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral

2014-11-26

Active, closed

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362Crohn's Disease

AbbVie

Observational

1,446

Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham

2014-08-28

Recruiting

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

NCT02071134Parkinson's Disease

Boston Scientific Corporation

Observational

1,500

Bristol, Glasgow, Liverpool, London, Newcastle, Oxford

2014-03-04

Active, closed

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NCT01872260Breast Cancer

DrugsAlpelisib·Ribociclib·Letrozole

Novartis Pharmaceuticals

Phase 1/2

259

Glasgow, Manchester

2013-10-22

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

Blackburn, Cambridge, Cardiff, Dundee, Glasgow, Guildford, Leeds, London

2013-10-14

Active, closed

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

DrugIbrutinib

Janssen Research & Development, LLC

Phase 3

539

Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2013-09-09

Active, closed

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561Ulcerative Colitis (UC)

AbbVie

Observational

8,250

Warrington, Darlington, Plymouth, Poole, Hull, London, Basingstoke, Glasgow

2013-04-29

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

Barnstaple, Birmingham, Blackpool, Bristol, Chelmsford, Glasgow, Harrow, Leeds

2012-01

Active, closed

Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study

NCT03343171Osteoarthritis, Avascular Necrosis, Inflammatory Arthritis, Post-traumatic Arthritis

Zimmer Biomet

Observational

203

Glasgow, Oxford, Southampton

2010-09-15

Active, closed

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

NCT00750841Solid Tumors

DrugCediranib Maleate

AstraZeneca

Phase 1

Dundee, Glasgow, London

2008-09-09

Recruiting

Pompe Disease Registry Protocol

NCT00231400Glycogen Storage Disease Type II, Pompe Disease

Genzyme, a Sanofi Company

Observational

2,000

Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne

2004-09-15

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/city/glasgow

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 437 of those studies with a site in Glasgow.

How many clinical trials are recruiting in Glasgow?

212 of the 437 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 3 have not yet opened recruitment, 207 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Glasgow), 437 studies
Phase	Studies	Recruiting	Share
Phase 3	232	104	53.1%
Phase 2	69	32	15.8%
Phase 1/2	41	24	9.4%
Observational	33	19	7.6%
Phase 1	25	14	5.7%
Phase 2/3	23	14	5.3%
Not applicable	10	3	2.3%
Phase 4	4	2	0.9%

Most active sponsors

Lead sponsors with the most studies (Glasgow)
Lead sponsor	Studies	Recruiting
AstraZeneca	35	21
Merck Sharp & Dohme LLC	22	11
Hoffmann-La Roche	16	6
Pfizer	16	5
Novartis Pharmaceuticals	15	8
AbbVie	12	2
Janssen Research & Development, LLC	12	5
Eli Lilly and Company	11	8
Bristol-Myers Squibb	9	7
argenx	8	3

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.